Volume | 1,106,208 |
|
|||||
News | - | ||||||
Day High | 8.275 | Low High |
|||||
Day Low | 7.64 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Vir Biotechnology Inc | VIR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.74 | 7.64 | 8.275 | 8.23 | 7.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
12,811 | 1,106,208 | $ 8.07 | $ 8,926,373 | - | 7.61 - 27.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:34:32 | formt | 100 | $ 8.22 | USD |
Vir Biotechnology Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.11B | 135.03M | - | 86.18M | -615.06M | -4.55 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vir Biotechnology News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VIR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.95 | 8.40 | 7.61 | 7.97 | 921,302 | 0.27 | 3.40% |
1 Month | 10.14 | 10.29 | 7.61 | 8.79 | 837,864 | -1.92 | -18.93% |
3 Months | 8.97 | 12.00 | 7.61 | 9.98 | 1,029,385 | -0.75 | -8.36% |
6 Months | 8.38 | 12.00 | 7.61 | 9.69 | 1,126,938 | -0.16 | -1.91% |
1 Year | 24.75 | 27.48 | 7.61 | 12.78 | 1,182,135 | -16.53 | -66.79% |
3 Years | 49.39 | 58.00 | 7.61 | 25.06 | 1,147,029 | -41.17 | -83.36% |
5 Years | 16.15 | 141.01 | 7.61 | 30.74 | 1,133,314 | -7.93 | -49.10% |
Vir Biotechnology Description
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. |